{"id":9138,"date":"2023-07-10T13:50:44","date_gmt":"2023-07-10T11:50:44","guid":{"rendered":"https:\/\/www.afaf.asso.fr\/?p=9138"},"modified":"2023-07-10T13:50:46","modified_gmt":"2023-07-10T11:50:46","slug":"information-importante-omaveloxolone","status":"publish","type":"post","link":"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/","title":{"rendered":"INFORMATION IMPORTANTE OMAVELOXOLONE"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">La soci\u00e9t\u00e9 Reata Pharmaceuticals, Inc. a d\u00e9pos\u00e9 le 3 Juillet 2023 en France le dossier d\u2019acc\u00e8s pr\u00e9coce pour le SKYCLARYS (omaveloxolone) aupr\u00e8s de la Haute Autorit\u00e9 de Sant\u00e9 (HAS) et de l\u2019Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les agences ont 3 mois au maximum pour statuer sur cette demande, donc jusqu\u2019au 3 Octobre 2023.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ensuite le laboratoire Reata Pharmaceuticals, Inc. dispose de 2 mois pour rendre la mol\u00e9cule disponible aupr\u00e8s des patients \u00e9ligibles.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tout le monde est \u00e0 pied d\u2019\u0153uvre, y compris l\u2019AFAF bien s\u00fbr, pour pr\u00e9parer tout ce qui est n\u00e9cessaire dans le cas d\u2019une r\u00e9ponse positive, que l\u2019on esp\u00e8re tous, pour ce 1er traitement approuv\u00e9 dans l\u2019Ataxie de Friedreich.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nous vous tiendrons bien entendu inform\u00e9s de la suite, de nombreuses autres r\u00e9unions sont d\u00e9j\u00e0 pr\u00e9vues. Nous esp\u00e9rons un acc\u00e8s \u00e0 toutes et \u00e0 tous d\u00e9but 2024.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La soci\u00e9t\u00e9 Reata Pharmaceuticals, Inc. a d\u00e9pos\u00e9 le 3 Juillet 2023 en France le dossier d\u2019acc\u00e8s pr\u00e9coce pour le SKYCLARYS (omaveloxolone) aupr\u00e8s de la Haute Autorit\u00e9 de Sant\u00e9 (HAS) et de l\u2019Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM). Les agences ont 3 mois au maximum pour statuer sur cette demande, [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":9137,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"ocean_front_end_style_editor":"no","ocean_post_layout":"","ocean_both_sidebars_style":"","ocean_both_sidebars_content_width":0,"ocean_both_sidebars_sidebars_width":0,"ocean_sidebar":"0","ocean_second_sidebar":"0","ocean_disable_margins":"enable","ocean_add_body_class":"","ocean_shortcode_before_top_bar":"","ocean_shortcode_after_top_bar":"","ocean_shortcode_before_header":"","ocean_shortcode_after_header":"","ocean_has_shortcode":"","ocean_shortcode_after_title":"","ocean_shortcode_before_footer_widgets":"","ocean_shortcode_after_footer_widgets":"","ocean_shortcode_before_footer_bottom":"","ocean_shortcode_after_footer_bottom":"","ocean_display_top_bar":"default","ocean_display_header":"default","ocean_header_style":"","ocean_center_header_left_menu":"0","ocean_custom_header_template":"0","ocean_custom_logo":0,"ocean_custom_retina_logo":0,"ocean_custom_logo_max_width":0,"ocean_custom_logo_tablet_max_width":0,"ocean_custom_logo_mobile_max_width":0,"ocean_custom_logo_max_height":0,"ocean_custom_logo_tablet_max_height":0,"ocean_custom_logo_mobile_max_height":0,"ocean_header_custom_menu":"0","ocean_menu_typo_font_family":"0","ocean_menu_typo_font_subset":"","ocean_menu_typo_font_size":0,"ocean_menu_typo_font_size_tablet":0,"ocean_menu_typo_font_size_mobile":0,"ocean_menu_typo_font_size_unit":"px","ocean_menu_typo_font_weight":"","ocean_menu_typo_font_weight_tablet":"","ocean_menu_typo_font_weight_mobile":"","ocean_menu_typo_transform":"","ocean_menu_typo_transform_tablet":"","ocean_menu_typo_transform_mobile":"","ocean_menu_typo_line_height":0,"ocean_menu_typo_line_height_tablet":0,"ocean_menu_typo_line_height_mobile":0,"ocean_menu_typo_line_height_unit":"","ocean_menu_typo_spacing":0,"ocean_menu_typo_spacing_tablet":0,"ocean_menu_typo_spacing_mobile":0,"ocean_menu_typo_spacing_unit":"","ocean_menu_link_color":"","ocean_menu_link_color_hover":"","ocean_menu_link_color_active":"","ocean_menu_link_background":"","ocean_menu_link_hover_background":"","ocean_menu_link_active_background":"","ocean_menu_social_links_bg":"","ocean_menu_social_hover_links_bg":"","ocean_menu_social_links_color":"","ocean_menu_social_hover_links_color":"","ocean_disable_title":"default","ocean_disable_heading":"default","ocean_post_title":"","ocean_post_subheading":"","ocean_post_title_style":"","ocean_post_title_background_color":"","ocean_post_title_background":0,"ocean_post_title_bg_image_position":"","ocean_post_title_bg_image_attachment":"","ocean_post_title_bg_image_repeat":"","ocean_post_title_bg_image_size":"","ocean_post_title_height":0,"ocean_post_title_bg_overlay":0.5,"ocean_post_title_bg_overlay_color":"","ocean_disable_breadcrumbs":"default","ocean_breadcrumbs_color":"","ocean_breadcrumbs_separator_color":"","ocean_breadcrumbs_links_color":"","ocean_breadcrumbs_links_hover_color":"","ocean_display_footer_widgets":"default","ocean_display_footer_bottom":"default","ocean_custom_footer_template":"0","ocean_post_oembed":"","ocean_post_self_hosted_media":"","ocean_post_video_embed":"","ocean_link_format":"","ocean_link_format_target":"self","ocean_quote_format":"","ocean_quote_format_link":"post","ocean_gallery_link_images":"off","ocean_gallery_id":[],"footnotes":""},"categories":[43],"tags":[],"class_list":["post-9138","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-informations_recherche","entry","has-media","owp-thumbs-layout-horizontal","owp-btn-normal","owp-tabs-layout-section","has-no-thumbnails"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INFORMATION IMPORTANTE OMAVELOXOLONE - Association Fran\u00e7aise Ataxie de Friedreich<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INFORMATION IMPORTANTE OMAVELOXOLONE - Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"og:description\" content=\"La soci\u00e9t\u00e9 Reata Pharmaceuticals, Inc. a d\u00e9pos\u00e9 le 3 Juillet 2023 en France le dossier d\u2019acc\u00e8s pr\u00e9coce pour le SKYCLARYS (omaveloxolone) aupr\u00e8s de la Haute Autorit\u00e9 de Sant\u00e9 (HAS) et de l\u2019Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM). Les agences ont 3 mois au maximum pour statuer sur cette demande, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/\" \/>\n<meta property=\"og:site_name\" content=\"Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-10T11:50:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-10T11:50:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2023\/07\/Skyclarys.png\" \/>\n\t<meta property=\"og:image:width\" content=\"349\" \/>\n\t<meta property=\"og:image:height\" content=\"144\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Caroline Gaboriau\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline Gaboriau\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/10\\\/information-importante-omaveloxolone\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/10\\\/information-importante-omaveloxolone\\\/\"},\"author\":{\"name\":\"Caroline Gaboriau\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/7366aa03c1779ab28140e42231ed7b28\"},\"headline\":\"INFORMATION IMPORTANTE OMAVELOXOLONE\",\"datePublished\":\"2023-07-10T11:50:44+00:00\",\"dateModified\":\"2023-07-10T11:50:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/10\\\/information-importante-omaveloxolone\\\/\"},\"wordCount\":166,\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/10\\\/information-importante-omaveloxolone\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Skyclarys.png\",\"articleSection\":[\"Informations sur la recherche\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/10\\\/information-importante-omaveloxolone\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/10\\\/information-importante-omaveloxolone\\\/\",\"name\":\"INFORMATION IMPORTANTE OMAVELOXOLONE - Association Fran\u00e7aise Ataxie de Friedreich\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/10\\\/information-importante-omaveloxolone\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/10\\\/information-importante-omaveloxolone\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Skyclarys.png\",\"datePublished\":\"2023-07-10T11:50:44+00:00\",\"dateModified\":\"2023-07-10T11:50:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/10\\\/information-importante-omaveloxolone\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/10\\\/information-importante-omaveloxolone\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/10\\\/information-importante-omaveloxolone\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Skyclarys.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Skyclarys.png\",\"width\":349,\"height\":144},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/10\\\/information-importante-omaveloxolone\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INFORMATION IMPORTANTE OMAVELOXOLONE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"description\":\"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.afaf.asso.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"width\":1181,\"height\":709,\"caption\":\"Association Fran\u00e7aise Ataxie de Friedreich\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/7366aa03c1779ab28140e42231ed7b28\",\"name\":\"Caroline Gaboriau\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g\",\"caption\":\"Caroline Gaboriau\"},\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/author\\\/caroline_gaboriau\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INFORMATION IMPORTANTE OMAVELOXOLONE - Association Fran\u00e7aise Ataxie de Friedreich","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/","og_locale":"fr_FR","og_type":"article","og_title":"INFORMATION IMPORTANTE OMAVELOXOLONE - Association Fran\u00e7aise Ataxie de Friedreich","og_description":"La soci\u00e9t\u00e9 Reata Pharmaceuticals, Inc. a d\u00e9pos\u00e9 le 3 Juillet 2023 en France le dossier d\u2019acc\u00e8s pr\u00e9coce pour le SKYCLARYS (omaveloxolone) aupr\u00e8s de la Haute Autorit\u00e9 de Sant\u00e9 (HAS) et de l\u2019Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM). Les agences ont 3 mois au maximum pour statuer sur cette demande, [&hellip;]","og_url":"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/","og_site_name":"Association Fran\u00e7aise Ataxie de Friedreich","article_published_time":"2023-07-10T11:50:44+00:00","article_modified_time":"2023-07-10T11:50:46+00:00","og_image":[{"width":349,"height":144,"url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2023\/07\/Skyclarys.png","type":"image\/png"}],"author":"Caroline Gaboriau","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Caroline Gaboriau","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/#article","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/"},"author":{"name":"Caroline Gaboriau","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/7366aa03c1779ab28140e42231ed7b28"},"headline":"INFORMATION IMPORTANTE OMAVELOXOLONE","datePublished":"2023-07-10T11:50:44+00:00","dateModified":"2023-07-10T11:50:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/"},"wordCount":166,"publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2023\/07\/Skyclarys.png","articleSection":["Informations sur la recherche"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/","url":"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/","name":"INFORMATION IMPORTANTE OMAVELOXOLONE - Association Fran\u00e7aise Ataxie de Friedreich","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/#primaryimage"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2023\/07\/Skyclarys.png","datePublished":"2023-07-10T11:50:44+00:00","dateModified":"2023-07-10T11:50:46+00:00","breadcrumb":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/#primaryimage","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2023\/07\/Skyclarys.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2023\/07\/Skyclarys.png","width":349,"height":144},{"@type":"BreadcrumbList","@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.afaf.asso.fr\/"},{"@type":"ListItem","position":2,"name":"INFORMATION IMPORTANTE OMAVELOXOLONE"}]},{"@type":"WebSite","@id":"https:\/\/www.afaf.asso.fr\/#website","url":"https:\/\/www.afaf.asso.fr\/","name":"Association Fran\u00e7aise Ataxie de Friedreich","description":"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich","publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.afaf.asso.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.afaf.asso.fr\/#organization","name":"Association Fran\u00e7aise Ataxie de Friedreich","url":"https:\/\/www.afaf.asso.fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","width":1181,"height":709,"caption":"Association Fran\u00e7aise Ataxie de Friedreich"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/7366aa03c1779ab28140e42231ed7b28","name":"Caroline Gaboriau","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g","caption":"Caroline Gaboriau"},"url":"https:\/\/www.afaf.asso.fr\/author\/caroline_gaboriau\/"}]}},"_links":{"self":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/9138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/comments?post=9138"}],"version-history":[{"count":0,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/9138\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media\/9137"}],"wp:attachment":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media?parent=9138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/categories?post=9138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/tags?post=9138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}